Current approaches—including CD3 redirection and T cell checkpoint inhibitors—are constrained by narrow therapeutic indices and the inability to overcome tumor-microenvironment barriers, leaving major clinical benefit untapped.
We redirect and reawaken the patient’s immune response by harnessing specialized immune cell subsets and highly selective tumor antigens, unlocking a fundamentally new generation of immunotherapies.
